Literature DB >> 2980214

Neuron specific enolase-positive breast carcinomas.

B Erikstein1, J M Nesland, L Ottestad, E Lund, J V Johannessen.   

Abstract

Ninety-eight patients treated for breast carcinomas were followed from 54 to 75 months after primary diagnosis. All had undergone a modified radical mastectomy with removal of axillary lymph nodes. 36 breast carcinomas were NSE-positive and 62 were negative. NSE-positive tumours were significantly more frequently estrogen receptor-positive than the NSE-negative tumours, and the estrogen receptor values were higher in the NSE-positive groups. Patients with NSE-positive tumours and patients with NSE-negative tumours did not differ with regard to presence of lymph node metastases at the time of primary surgery. However, the study showed that patients with NSE-positive tumours had a tendency towards more lymph node metastases after primary surgical intervention, but a better outcome than patients with NSE-negative tumours and metastases. This study, with a 5-year follow up, failed to demonstrate any major prognostic significance of immunostaining for NSE.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2980214

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  3 in total

1.  Prevalence and Prognostic Significance of Neuroendocrine Differentiation in Colorectal Carcinomas.

Authors:  Ricardo V. Lloyd; Georgene Schroeder; Mitchel D. Bauman; James E. Krook; Long Jin; Richard M. Goldberg; Gist H. Farr
Journal:  Endocr Pathol       Date:  1998       Impact factor: 3.943

2.  Arsenic, cadmium and neuron specific enolase (ENO2, γ-enolase) expression in breast cancer.

Authors:  Maureen A Soh; Scott H Garrett; Seema Somji; Jane R Dunlevy; Xu Dong Zhou; Mary Ann Sens; Chandra S Bathula; Christina Allen; Donald A Sens
Journal:  Cancer Cell Int       Date:  2011-11-18       Impact factor: 5.722

3.  Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase, creatine kinase and enolase activity and isoenzymes in breast carcinoma.

Authors:  N Durany; J Joseph; O M Jimenez; F Climent; P L Fernández; F Rivera; J Carreras
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.